(Total Views: 275)
Posted On: 09/28/2018 7:55:27 PM
Post# of 4527
$RDGL - IsoPet canine soft-tissue sarcoma treatment delivers ‘complete response’
Vivos Inc. will present the results of the first successful therapy to treat soft tissue sarcoma in a dog at the Veterinary Cancer Society’s annual conference
September 28, 2018
Vivos Inc., a pharmaceutical company that develops minimally invasive treatments to combat cancer in humans and animals, reported that its signature product, IsoPet, was used to treat a hind-leg soft-tissue sarcoma in a Shetland sheepdog at the University of Missouri Veterinary Health Center in Columbia, Mo.
The treatment of the sarcoma resulted in a “complete response,” meaning tumor destruction and disappearance, together with a healthy recovery, according to veterinary oncologist Charles Maitz, DVM, PhD, DACVR-RO.
Results will be presented in at the Veterinary Cancer Society’s annual conference in Louisville, Ky., Oct. 17 – 20.
Post-treatment imaging and dosimetry provided confirmatory data addressing questions previously raised by U.S. Food and Drug Administration review panel, including:
Near-uniform placement by injection and interstitial perfusion within the tumor without vascular clearance to normal organs and tissues
Very high therapeutic ratios (radiation dose to the tumor relative to normal organs)
Effective, highly localized, high-dose radiotherapy, and complete absence of adverse side-effects in critical normal tissues
The University of Missouri is now advertising availability of IsoPet treatment for dogs and other species, including treatment of equine sarcoids.
Vivos Inc. will present the results of the first successful therapy to treat soft tissue sarcoma in a dog at the Veterinary Cancer Society’s annual conference
September 28, 2018
Vivos Inc., a pharmaceutical company that develops minimally invasive treatments to combat cancer in humans and animals, reported that its signature product, IsoPet, was used to treat a hind-leg soft-tissue sarcoma in a Shetland sheepdog at the University of Missouri Veterinary Health Center in Columbia, Mo.
The treatment of the sarcoma resulted in a “complete response,” meaning tumor destruction and disappearance, together with a healthy recovery, according to veterinary oncologist Charles Maitz, DVM, PhD, DACVR-RO.
Results will be presented in at the Veterinary Cancer Society’s annual conference in Louisville, Ky., Oct. 17 – 20.
Post-treatment imaging and dosimetry provided confirmatory data addressing questions previously raised by U.S. Food and Drug Administration review panel, including:
Near-uniform placement by injection and interstitial perfusion within the tumor without vascular clearance to normal organs and tissues
Very high therapeutic ratios (radiation dose to the tumor relative to normal organs)
Effective, highly localized, high-dose radiotherapy, and complete absence of adverse side-effects in critical normal tissues
The University of Missouri is now advertising availability of IsoPet treatment for dogs and other species, including treatment of equine sarcoids.
(0)
(0) Engineer by trade & Swing Trader at Heart!
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
